Sort by

Send to

Choose Destination

Links from PubMed

Items: 10


Renin-Angiotensin System Genes Polymorphisms and Long-Term Prognosis in Taiwanese Patients with Hypertension and Coronary Artery Disease.

Wu CK, Lee JK, Lin LY, Huang YT, Hwang JJ, Lin CL, Tseng CD, Chiang FT.

Acta Cardiol Sin. 2013 Jan;29(1):28-36.


Pharmacogenetic Risk Scores for Perindopril Clinical and Cost Effectiveness in Stable Coronary Artery Disease: When Are We Ready to Implement?

Luzum JA, Lanfear DE.

J Am Heart Assoc. 2016 Mar 28;5(3):e003440. doi: 10.1161/JAHA.116.003440. No abstract available.


Individualized Angiotensin-Converting Enzyme (ACE)-Inhibitor Therapy in Stable Coronary Artery Disease Based on Clinical and Pharmacogenetic Determinants: The PERindopril GENEtic (PERGENE) Risk Model.

Oemrawsingh RM, Akkerhuis KM, Van Vark LC, Redekop WK, Rudez G, Remme WJ, Bertrand ME, Fox KM, Ferrari R, Danser AH, de Maat M, Simoons ML, Brugts JJ, Boersma E; PERGENE investigators.

J Am Heart Assoc. 2016 Mar 28;5(3):e002688. doi: 10.1161/JAHA.115.002688.


Women and men with stable coronary artery disease have similar clinical outcomes: insights from the international prospective CLARIFY registry.

Steg PG, Greenlaw N, Tardif JC, Tendera M, Ford I, Kääb S, Abergel H, Fox KM, Ferrari R; CLARIFY Registry Investigators.

Eur Heart J. 2012 Nov;33(22):2831-40. doi: 10.1093/eurheartj/ehs289. Epub 2012 Aug 26.


Perindopril: the evidence of its therapeutic impact in hypertension.

Thomson A, Greenacre M.

Core Evid. 2007 Mar 31;2(1):63-79.


Different angiotensin-converting enzyme inhibitors have similar clinical efficacy after myocardial infarction.

Hansen ML, Gislason GH, Køber L, Schramm TK, Folke F, Buch P, Abildstrom SZ, Madsen M, Rasmussen S, Torp-Pedersen C.

Br J Clin Pharmacol. 2008 Feb;65(2):217-23. Epub 2007 Aug 15.


ACE inhibitors: back to prime time?

Gupta M, Verma S, Mancini GB.

Heart. 2007 Sep;93(9):1015-6. No abstract available.


Treatment of stable angina.

Ben-Dor I, Battler A.

Heart. 2007 Jul;93(7):868-74. Review. No abstract available.


Cost effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA study.

Briggs A, Mihaylova B, Sculpher M, Hall A, Wolstenholme J, Simoons M, Deckers J, Ferrari R, Remme WJ, Bertrand M, Fox K; EUROPA Trial Investigators.

Heart. 2007 Sep;93(9):1081-6. Epub 2006 Nov 29.

Items per page

Supplemental Content

Write to the Help Desk